Eli Lilly (LLY) Net Margin (2009 - 2026)

Eli Lilly has reported Net Margin for 17 years, with the latest figure at 37.36% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 1568.0% year-over-year to 37.36%; the trailing twelve-month figure through Mar 2026 stood at 34.99% (up 1232.0% YoY), and the FY2025 full-year result was 31.67%, up 816.0% from the prior year.
• Net Margin for Q1 2026 stood at 37.36%, up from 34.41% in the prior quarter.
• The five-year high for Net Margin was 37.36% in Q1 2026, with the low at 0.6% in Q3 2023.
• Historically, Net Margin has averaged 23.78% across 5 years, with a median of 24.36% in 2022.
• Annual changes were most pronounced in 2023 — Net Margin plunged 2152 bps — and 2025, when it surged 2323 bps.
• Eli Lilly's Net Margin stood at 26.54% in 2022, then retreated by 12 bps to 23.41% in 2023, then jumped by 39 bps to 32.59% in 2024, then grew by 6 bps to 34.41% in 2025, then gained by 9 bps to 37.36% in 2026.
• The last three Net Margin figures came in at 37.36% (Q1 2026), 34.41% (Q4 2025), and 31.72% (Q3 2025), per Business Quant data.